Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 264-092-6 | CAS number: 63310-16-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 29 November 1981 to 27 December 1981
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted in compliance with agreed protocols, with no or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do not affect the quality of the relevant results.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 982
- Report date:
- 1982
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
- Deviations:
- no
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- 9-Octadecenoic acid (Z)-, monoester with 1,2,3-propanetriol ester with boric acid (H3BO3)
- EC Number:
- 264-092-6
- EC Name:
- 9-Octadecenoic acid (Z)-, monoester with 1,2,3-propanetriol ester with boric acid (H3BO3)
- Cas Number:
- 63310-16-7
- Molecular formula:
- C21H39O5B (based on the representative structure below)
- IUPAC Name:
- 2-hydroxy-3-{[hydroxy({2-hydroxy-3-[(9Z)-octadec-9-enoyloxy]propoxy})boranyl]oxy}propyl (9Z)-octadec-9-enoate; 3-{[bis({2-hydroxy-3-[(9Z)-octadec-9-enoyloxy]propoxy})boranyl]oxy}-2-hydroxypropyl (9Z)-octadec-9-enoate; {2-hydroxy-3-[(9Z)-octadec-9-enoyloxy]propoxy}boronic acid
- Test material form:
- liquid: viscous
- Details on test material:
- - EC no.: 264-092-6
- Physical state: liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Wilmington, Massachusetts, USA
- Age at study initiation: 67 days (males); 78 days (females)
- Weight at study initiation: 281 - 353 g (males); 202 - 283 g (females)
- Housing: individually in wire-bottom cages
- Diet: Purina Certified Rodent Chow #5002 ad libitum
- Water: ad libitum
- Acclimation period: 17 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): approximately 21 ºC
- Humidity (%): 61 - 78 %
- Photoperiod (hrs dark / hrs light): 12 hours dark / 12 hours light
IN-LIFE DATES: From 29 November 1981 to 27 December 1981
Administration / exposure
- Type of coverage:
- not specified
- Vehicle:
- other: mineral oil
- Details on exposure:
- TEST SITE
- The back of each rat was clipped free of hair prior to dosing on the first day of each week and as needed thereafter.
REMOVAL OF TEST SUBSTANCE
- The test material was removed 6 hours after application by wiping the animals backs using gauze squares moistened with diethyl ether.
TEST MATERIAL
- 1.0 mL/kg test material at the following concentrations was applied to each dose group: unchanged (high-dose), 50% (w/w) in mineral oil (mid-dose), 20% (w/w) in mineral oil (low-dose), or 1.0 mL/kg mineral oil (control group). The test material was applied to an unabraded site which were alternated between the scapula and the sacrum to reduce skin irritation.
USE OF RESTRAINERS FOR PREVENTING INGESTION: yes
- To prevent oral ingestion of the test material each animal was fitted with a Queen Ann collar prior to dosing each day and removed at the end of the 6 hour exposure period. - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Animals were treated for 6 hours per day for an average of five days per week (six days during the first week, five days during the second and third weeks, and four days during the fourth week) for four consecutive weeks.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
100%, 50%, 20% and 0% w/w
Basis:
- No. of animals per sex per dose:
- 15 males and 15 females
- Control animals:
- yes
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: No data
DETAILED CLINICAL OBSERVATIONS: No data
DERMAL IRRITATION: Yes
- Time schedule for examinations: at the beginning and end of each treatment period. Animals scored according to Draize et al (1944)
BODY WEIGHT: Yes
- Time schedule for examinations: at the beginning and end of each weekly treatment period and prior to sacrifice
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at sacrifice
- Anaesthetic used for blood collection: Yes (diethyl ether)
- Animals fasted: Yes (overnight prior to sacrifice)
- How many animals: 10 animals of each sex per dose group
- Parameters checked included: white blood cell count, red blood cell count, hemaglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin and mean corpuscular hemaglobin concentration. A differential count was also performed.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at sacrifice
- Anaesthetic used for blood collection: Yes (diethyl ether)
- Animals fasted: Yes (overnight prior to sacrifice)
- How many animals: 10 animals of each sex per dose group
- Parameters checked included: glucose, iron, calcium, phosphorus, uric acid, blood urea nitrogen, creatinine, sodium, potassium, chloride, lactate dehydrogenase, serum glutamic oxalacetic transminase, serum glutamic pyruvic transaminase, alkaline phosphatase, total bilirubin, direct bilirubin, indirect bilirubin, cholesterol, triglycerides, total protein, albumin and globulin.
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- All of the animals were fasted overnight prior to sacrifice. Terminal sacrifice was performed by exsanguination. Necropsy commenced four days following the last treatment and continued over the next three days until all of the animals had been sacrificed.
GROSS PATHOLOGY: Yes
- The following organs were examined for gross pathological changes and weighed: brain, heart, liver, gonads, kidneys and adrenals.
- The following organs and tissues were also examined for gross pathological changes: skin, spleen, pancreas, stomach, small and large intestine, uterus or seminal vesicles, bladder, heart, thymus, salivary glands, lungs, trachea, esophagus, thyroid and fat.
HISTOPATHOLOGY: Yes
- Samples of the tissues taken at necropsy, and any gross lesions observed, were preserved in 10% (v/v) neutral formalin and submitted for histopathological examination. - Statistics:
- Body weights, weekly body weight changes, organ weights, organ/body weight ratios, hematology and serum chemistry data were statistically analysed by one-way analysis of variance among the four test groups. Monocyte, eosinophil, basophil, and banded neutrophil differential counts were not statistically analysed since this data were very sparse. Incidences of histopathological changes were analysed using a Chi-Square Test with Yates' correction for continuity, or the Fisher's Exact Test.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- See "Details on results" for further information
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- See "Details on results" for further information
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No deaths occurred and no signs of toxicity were observed during the study.
DERMAL IRRITATION
At the end of the first week of treatment, very slight to well defined erythema appeared in male animals and very slight to moderate erythema appeared in female animals in an apparent dose-related manner. Very slight edema was also present in males in the high dose group and in females in the high and mid-dose groups. there was also a high incidence of dry, flaky and/or cracked skin in male and female animals. Skin irritation had subsided by the end of the second week of treatment and appeared sporadically in a few treated animals through the end of the study.
BODY WEIGHT AND WEIGHT GAIN
There were no significant differences in mean bodyweight, or bodyweight gain, between control and treated males or females during the study.
HAEMATOLOGY
THere were no significant differences between any hematological parameter between control and treated animals that could be attributed to treatment with the test material. There was a significant decrease in the mean percentage of neutrophils between control and treated males but since the decrease was not dose-related it was concluded not to be related to treatment with the test material.
CLINICAL CHEMISTRY
Mean serum calcium and phosphorus levels were significantly greater than control in male and female animals of all treatment groups. Mean blood urea nitrogen levels and mean blood urea nitrogen/creatinine ratios were significantly lower than control in female animals of all treatment groups. Mean serum alkaline phosphatase activity was significantly lower than the control in the mid- and low-dose groups but not in the high-dose group. None of the changes in serum chemistry were dose-related, and no other changes in serum chemistry were observed that could be attributed to treatment with the test material.
ORGAN WEIGHTS
There were no significant differences in mean organ weights or mean organ/body weight ratios between control and treated males. The mean left ovary weight was significantly lower than control in the female high and mid dose groups and the changes were apparently dose-related. There were no differences in the mean right ovary weight . Mean brain weight in females in the high dose group was significantly greater than control but there was no difference in the mean brain/body weight ratio between females in these two groups.
GROSS PATHOLOGY
At necropsy, no gross pathological changes were observed that could be attributed to treatment with the test material.
HISTOPATHOLOGY: NON-NEOPLASTIC
Microscopic examination of tissues from the control, low and high-dose groups did not reveal any histopathological changes or any significantly increased incidences of any pathological lesions that could be attributed to treatment with the test material.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No mortality or signs of toxicity were noted at this treatment level.
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 1: Incidence of Skin Irritation from 6 Days of Repeated Dermal Application of 1 mg/kg Test Material
Treatment group |
Males |
Females |
|||||
Erythema |
Edema |
Dry, flaky and/or cracked skin |
Erythema |
Edema |
Dry, flaky and/or cracked skin |
||
Mineral oil (control) |
3/15 |
0/15 |
7/15 |
0/15 |
0/15 |
0/15 |
|
20% (w/w) test material |
6/15 |
0/15 |
8/15 |
2/15 |
0/15 |
4/15 |
|
50% (w/w) test material |
5/15 |
0/15 |
5/15 |
9/15 |
2/15 |
10/15 |
|
100% test material |
11/15 |
5/15 |
12/15 |
10/15 |
6/15 |
12/15 |
Table 2: Organ Weights
Treatment group |
Males |
Females |
|||||||
Mineral oil control |
20% (w/w) test material |
50% (w/w) test material |
100%test material |
Mineral oil control |
20% (w/w) test material |
50% (w/w) test material |
100% test material |
||
Organ |
|||||||||
Brain (g) |
2.0 |
2.0 |
2.0 |
2.0 |
1.9 |
1.9 |
1.9 |
2.0† |
|
Liver (g) |
10.3 |
10.5 |
10.5 |
10.4 |
7.0 |
7.2 |
7.1 |
7.3 |
|
Heart (g) |
1.2 |
1.2 |
1.2 |
1.2 |
0.9 |
0.8 |
0.8 |
0.9 |
|
Left kidney (g) |
1.3 |
1.3 |
1.3 |
1.4 |
0.9 |
0.9 |
0.9 |
0.9 |
|
Right kidney (g) |
1.3 |
1.3 |
1.4 |
1.3 |
0.9 |
0.9 |
0.9 |
0.9 |
|
Left testicle (g)/ovary (mg) |
1.5 |
1.6 |
1.6 |
1.6 |
73.4 |
71.7 |
62.9† |
59.5† |
|
Right testicle (g)/ovary (mg) |
1.5 |
1.6 |
1.7 |
1.6 |
64.0 |
69.9 |
66.2 |
63.4 |
|
Left adrenal (mg) |
32.6 |
35.2 |
32.8 |
31.7 |
41.4 |
40.8 |
41.9 |
40.1 |
|
Right adrenal (mg) |
31.1 |
31.9 |
29.4 |
31.8 |
35.0 |
38.6 |
37.8 |
37.1 |
† Significantly different from control (p ≤ 0.01)
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of the study, subacute dermal treatment of male and female rats with test material did not cause any mortality or any signs of toxicity. Mild skin irritation appeared in both sexes during the first week of the study, but subsided thereafter. The statistically significant changes in mean serum calcium levels, serum phosphorus levels, blood urea nitrogen, blood urea nitrogen/creatinine rations, left ovary weight, left ovary/body weight ratio and brain weight were not considered biologically significant. No other significant changes occurred that could be attributed to treatment with the test material. The No Observed Adverse Effect Level was subsequently determined to be 1000 mg/kg bw/day. The study is considered to be reliable, relevant and adequate for risk assessment and classification and labelling purposes.
- Executive summary:
The dermal repeat dose toxicity of the test material was determined following a methodology equivalent to standardised guideline OECD 410. Groups of fifteen male and fifteen female rats were dermally administered 20% w/w, 50% w/w or 100% test material in mineral oil for a period of 4 weeks. Animals were treated for 6 hours per day, six times a week during week 1, fives time per week during weeks 2 and 3 and four times a week during week 4. An additional group of fifteen males and fifteen females were treated with mineral oil alone and served as controls. Clinical observations, bodyweights and skin irritation parameters were measured throughout the study. At the end of the study, the animals were killed and subjected to an examination post mortem. Cardiac blood samples were taken for clinical pathology, selected organs were weighed and specified tissues were taken for subsequent histopathology examination. Under the conditions of the study, subacute dermal treatment of male and female rats with test material did not cause any mortality or any signs of toxicity. Mild skin irritation appeared in both sexes during the first week of the study, but subsided thereafter. The statistically significant changes in mean serum calcium levels, serum phosphorus levels, blood urea nitrogen, blood urea nitrogen/creatinine ratios, left ovary weight, left ovary/body weight ratio and brain weight were not considered biologically significant. No other significant changes occurred that could be attributed to treatment with the test material. The No Observed Adverse Effect Level was subsequently determined to be 1000 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
